If you're looking to bolster your portfolio with some blue chip shares, you may want to look at the two listed below.
Here's why these blue chip ASX 200 shares are highly rated right now:
CSL Limited (ASX: CSL)
The first ASX 200 blue chip share that analysts are saying investors should buy is biotherapeutics giant, CSL. Over the last century, the company has developed a range of lifesaving and lucrative plasma therapies and vaccines. It is also in the process of acquiring Vifor Pharma, which is focused on iron deficiency, nephrology and cardio-renal therapies.
Morgans is positive on the company and believes it is on the verge of returning to form after dificulties during the pandemic. Morgans commented:
"Promisingly, plasma collections continue to improve, although remain slightly below pre-pandemic levels, and while industry wide issues remain (eg Omicron; staffing; increase costs), the worst appears behind us."
"While near term challenges remain, the ongoing recovery in plasma collections, coupled with management's confidence, paints a favourable earnings picture."
Morgans has an add rating and $327.60 price target on its shares.
Goodman Group (ASX: GMG)
Another ASX 200 blue chip share to consider is Goodman. It is an integrated property company with operations across the globe.
Goodman has been growing at a solid rate for well over a decade and the team at Citi expect this trend to continue.
"GMG's 1H22 EPS of 41.9c was 12% ahead of Visible Alpha consensus (37.3c) and 6% ahead of Citi (39.5c). FY22 EPS guidance was upgraded for the 2nd time in 6 months to 20% growth, or EPS of 78.7c, +1.5% ahead of ingoing consensus of 77.5c. FY22 DPS guidance was retained at 30c."
"We continue to see guidance as conservative, with our EPS estimates rising 5% in FY22 and c. 6% thereafter. We now forecast c. 23% EPS growth in FY22 and c. 19% EPS CAGR from FY21-FY24. Our TP increases 5% on higher asset values and higher earnings. GMG remains OUR top pick in the sector."
Citi has a buy rating and $29.50 price target on its shares.
